Quantcast
 
Read Larry Connors' blogShort Term Trading Strategies


 

Zacks Analyst Blog Highlights: CF Industries Holdings, Inc., Amgen, Inc., Vimpel-Communications, Mobile TeleSystems OJSC and The Procter & Gamble Co.

Wed. September 17, 2008; Posted: 06:00 AM
Stocks RSS
CHICAGO, Sep 17, 2008 (BUSINESS WIRE) -- VIP | Quote | Chart | News | PowerRating -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: CF Industries Holdings, Inc. (NYSE: CF), Amgen, Inc. (Nasdaq: AMGN), Vimpel-Communications (NYSE: VIP), Mobile TeleSystems OJSC (NYSE: MBT | Quote | Chart | News | PowerRating) and Procter & Gamble Co. (NYSE: PG).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579

Here are highlights from Wednesday's Analyst Blog:

CF Industries Keeps It Growing

CF Industries Holdings, Inc. (NYSE: CF | Quote | Chart | News | PowerRating) has leading market shares in many key fertilizers. Strong domestic and international grain markets have produced an exceptionally high global demand for fertilizer, translating into substantially higher selling prices for all the products.

The company is likely to benefit from the proposed nitrogen facility in Peru, which will address the nitrogen demand on the west coast of Central and South America as well as Mexico, which does not have a nitrogen facility. As a result, we rate the shares a Buy with a target of $130.

Amgen Stays a Long-Term Hold

Amgen, Inc.'s (Nasdaq: AMGN | Quote | Chart | News | PowerRating) results over the past few quarters demonstrate the challenging, but stabilizing ESA market. Nevertheless, we still feel as though the pipeline is significantly undervalued, and we continue to recommend the name as a long-term Hold within the biotechnology sector.

Recent positive news on phase III denosumab is a big reason we continue to be positive on Amgen. The ESA trends are stabilizing, but it will still take a few more quarters to see exactly how the ODAC meeting and finalized label will affect sales. In the meantime, investors should focus their time on just how big denosumab and motesanib can be, because they are the next wave of potential growth.

VimpelCom Maintaining Strength

Vimpel-Communications (NYSE: VIP | Quote | Chart | News | PowerRating) delivered better-than-expected operating results in the most recent quarter, beating our estimates with strong revenue and customer growth across all its markets.

We reiterate our Buy rating based on financial metric estimates which we believe are attainable. VimpelCom is trading at 10.2x our 2008 EPADS estimates which is significantly below historical levels in previous quarters, although this metric remains at a premium to its major competitor, Mobile TeleSystems (NYSE: MBT | Quote | Chart | News | PowerRating) (its closest Russian peer). VimpelCom's shares have lost approximately 50% of its value since a 52-week high reached in December 2007.

Procter & Gamble Won't Outperform

Procter & Gamble's (NYSE: PG | Quote | Chart | News | PowerRating) management is committed to a growth strategy based on driving volume through product innovation and increasing penetration into developing markets and expanding profitability by focusing on higher margin categories. The plan is meeting with success in terms of top-line expansion, volume growth, and higher earnings.

Though the Gillette acquisition was accretive to earnings in fiscal 2008, the gross margin was negatively impacted by increased commodity and energy costs. The Hold recommendation is maintained.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

SOURCE: Zacks.com

Zacks.com Mark Vickery Web Content Editor 312-265-9380 Visit: www.zacks.com

For full details on Amgen Inc (AMGN) click here. Amgen Inc (AMGN) has Short Term PowerRatings of 5. Details on Amgen Inc (AMGN) Short Term PowerRatings is available at This Link.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Related News [AMGN]
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.